Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia
Abd el hameed, A., azab, M., Baraka, A., Elshorbagy, S. (2023). Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia. EKB Journal Management System, 29(2), 469-478. doi: 10.21608/zumj.2021.89473.2310
Abdullah Mohamad Abd el hameed; mervat azab; Ahmad Mohamed Baraka; Shereen Elshorbagy. "Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia". EKB Journal Management System, 29, 2, 2023, 469-478. doi: 10.21608/zumj.2021.89473.2310
Abd el hameed, A., azab, M., Baraka, A., Elshorbagy, S. (2023). 'Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia', EKB Journal Management System, 29(2), pp. 469-478. doi: 10.21608/zumj.2021.89473.2310
Abd el hameed, A., azab, M., Baraka, A., Elshorbagy, S. Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia. EKB Journal Management System, 2023; 29(2): 469-478. doi: 10.21608/zumj.2021.89473.2310

Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia

Zagazig University Medical Journal
Article 22, Volume 29, Issue 2, March 2023, Page 469-478  XML PDF (392.14 K)
Document Type: Original Article
DOI: 10.21608/zumj.2021.89473.2310
View on SCiNiTO View on SCiNiTO
Authors
Abdullah Mohamad Abd el hameed email 1; mervat azab2; Ahmad Mohamed Baraka3; Shereen Elshorbagy4
1Clinical pathology. Faculty of medicine. Zagazig university. El sharia governorate.eygpt
2Clinical Pathology-Faculty of Medicine Zagazig University-Egypt
3Department of clinical pathology , faculty of medicine , Zagazig University
4medical oncology-Faculty of Medicine Zagazig University-Egypt
Abstract
Abstract:

Background: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the world. CLL involves the abnormal activation of Wingless-type (Wnt) signaling pathway. Lymphoid enhancer-binding factor 1 (LEF1) is a member of the LEF1/T-cell factor (TCF) family of transcription factors
Aim: To evaluate LEF1 expression in CLL and its impact on risk stratification and response to therapy.
Subjects and methods: This study was conducted on 32 patients recently diagnosed as chronic lymphocytic leukemia . Complete blood picture, LDH , bone marrow aspiration , immunophenotyping , cytogenetic analysis and assessment of LEF1 expression by real time PCR were done for all patients.
Results: The prognostic value for LEF1 was evaluated. There was a significant difference between Low LEF group and high LEF group as regards mortality (P .006), All the patients in low LEF group were alive at the end of follow up period, while in high LEF group five were alive at the end of follow up period and two died during the study. The overall survival of patient's low LEF level was longer than patients with high LEF level. Such difference was statistically significant (P=0.005).
Conclusion: level of expression of LEF in CLL patients may be valuabale in predicting the survival
Keywords
CLL; LEF1; real-time PCR
Statistics
Article View: 184
PDF Download: 71